1. Mindray Medical leads GEM:
As the pioneer of GEM market value, Mindray Medical's every move has attracted much attention, and lifting the ban is no exception. According to the closing price of 10, 1 1, Mindray Medical's market value is as high as 68.8 billion yuan, and the stock price is under great pressure. Mindray Medical expects that the company's revenue in the third quarter will be1182.2 billion yuan to128.5 billion yuan, a year-on-year increase of15%-25%; The net profit was 3.476 billion yuan to 3.766 billion yuan, a year-on-year increase of 20% to 30%. This performance forecast is quite eye-catching, and it also gives the capital market a "reassurance", which to some extent eliminates the expectation that the lifting of the ban will bring selling pressure. 10 10/0/6, Mindray Medical's share price fell by 4.29% on the day when the stock was lifted, but closed up by 4. 15% the next day, almost smoothing out the previous day's decline. The rise in this stock turned out to be a false alarm. Since the listing of 10 last year, Mindray Medical's share price has been leaping forward, from the opening price of 57.56 yuan to the highest price of this year 196.6 yuan, with a cumulative increase of 229.88% and a market value of over 200 billion yuan, leading the growth of the Growth Enterprise Market.
Second, how does Mindray Medical's 68 billion stabilize the GEM?
A lot of R&D expenses are not wasted, but converted into remarkable scientific research achievements. For example, in the first half of the year, Mindray Medical launched a number of heavy new products and upgraded versions, such as DC-80 X-Insight high-end desktop color Doppler ultrasound, BS-2000M automatic biochemical analyzer, CL-6000i M2 automatic chemiluminescence immunoassay analyzer and other companies launched the first completely independent test module "assembly line M6000" in China. Through modular combination, four independent detection systems of biochemistry, immunity, blood and coagulation are innovatively integrated, and the detection process is fully automated and standardized. In terms of patent achievements, Mindray Medical ranks first among domestic enterprises. As of the first half of this year, the company has applied for 4,248 patents and authorized more than 2,700 patents. According to the list of the top 50 invention patents of the National Enterprise Technology Center published by the National Development and Reform Commission, Mindray is the only medical device company on the list, along with Huawei, PetroChina and Gree.
To sum up, bull stocks are not made in a day, and the king of stocks is not in name only, but the result of accumulated practice. Similarly, the scale of investment also lies in the intrinsic value of the company.